Page last updated: 2024-12-10

fti 277

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FTI 277: a ras CAAX (C - Cys; A - aliphatic amino acid; X - Ser or Met) peptidomimetic; inhibits farnesyltransferase; blocks Ras oncogenic signaling by accumulating Ras/Raf complexes in the cytoplasm; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3005532
CHEMBL ID135561
SCHEMBL ID8365606
MeSH IDM0254708
PubMed CID71311821
SCHEMBL ID5078478
MeSH IDM0254708

Synonyms (33)

Synonym
fti-277
NCGC00165961-01
(s)-2-{[5-((r)-2-amino-3-mercapto-propylamino)-biphenyl-2-carbonyl]-amino}-4-methylsulfanyl-butyric acid methyl ester
bdbm50138764
CHEMBL135561 ,
methyl (2s)-2-[[4-[[(2r)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoate
SCHEMBL8365606
CS-3864
170006-73-2
HY-15872
l-methionine, n-((5-((2-amino-3-mercaptopropyl)amino)(1,1'-biphenyl)-2-yl)carbonyl)-, methyl ester, (r)-
cid 3005532
J-010593
methyl (5-(((r)-2-amino-3-mercaptopropyl)amino)-[1,1'-biphenyl]-2-carbonyl)-l-methioninate
(s)-methyl 2-(5-(((r)-2-amino-3-mercaptopropyl)amino)-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate
NCGC00165961-04
EX-A2211A
(s)-methyl2-(5-(((r)-2-amino-3-mercaptopropyl)amino)-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate
fti 277
fti-277 trifluoroacetate salt
n-[4-[2(r)-amino-3-mercaptopropyl]amino-2-phenylbenzoyl]methionine methyl ester trifluoroacetate salt
SCHEMBL5078478
1217447-06-7
AKOS024457080
fti-277 trifluoroacetate salt, >=95% (hplc), amorphous semi-solid
gjeffrdwfvscoj-pxpmwpizsa-n
n-[4-[2(r)-amino-3-mercaptopropyl]amino-2-phenylbenzoyl]methioninemethylestertrifluoroacetatesalt
(s)-methyl 2-(5-(((r)-2-amino-3-mercaptopropyl)amino)-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate 2,2,2-trifluoroacetate
methyl (2s)-2-[[4-[[(2r)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoate;2,2,2-trifluoroacetic acid
VGA00673
A927007
n-[[5-[[(2r)-2-amino-3-mercaptopropyl]amino][1,1'-biphenyl]-2-yl]carbonyl]-l-methionine methyl ester
(s)-methyl2-(5-(((r)-2-amino-3-mercaptopropyl)amino)-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoate2,2,2-trifluoroacetate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Exposure to a toxic dose of METH significantly decreased cell viability, and tyrosine hydroxylase phosphorylation, but increased c-Jun phosphorylation and active, GTP-bound Ras in cultured SH-SY5Y cells."( Farnesyltransferase inhibitor attenuates methamphetamine toxicity-induced Ras proteins activation and cell death in neuroblastoma SH-SY5Y cells.
Chetsawang, B; Govitrapong, P; Pirompul, N, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency1.99530.004023.8416100.0000AID485290
Chain A, Ferritin light chainEquus caballus (horse)Potency28.18385.623417.292931.6228AID485281
phosphopantetheinyl transferaseBacillus subtilisPotency15.84890.141337.9142100.0000AID1490
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency10.00000.354828.065989.1251AID504847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)IC50 (µMol)0.02020.00050.471610.0000AID1371353; AID164306
Protein farnesyltransferase subunit betaHomo sapiens (human)IC50 (µMol)0.02020.00050.21772.5000AID1371353; AID164306
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
transforming growth factor beta receptor signaling pathwayProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of Rac protein signal transductionProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of tubulin deacetylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of deacetylase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
lipid metabolic processProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
Rab geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
receptor tyrosine kinase bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
alpha-tubulin bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
molecular adaptor activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
zinc ion bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
plasma membraneProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytoplasmProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytosolProtein farnesyltransferase subunit betaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID164306Inhibition of Trypanosoma brucei protein farnesyltransferase2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
AID3339Effective dose against murine 3T3 fibroblasts cells2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
AID144118Inhibition of Ha-Ras processing in NIH3T3 Ras transformed cells.1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
AID1335610Inhibition of recombinant FT (unknown origin) using FPP as substrate preincubated for 5 mins followed by protein addition measured over 20 mins by fluorescence assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Pyrazole-based potent inhibitors of GGT1: Synthesis, biological evaluation, and molecular docking studies.
AID1371353Inhibition of FTase isolated from human Burkitt's lymphoma cells assessed as decrease in transfer of [3H]farnesyl from [3H]farnesyl PPi to H-Ras-CVLS2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.
AID215880Effective dose required to inhibit the growth of Trypanosoma brucei rhodesiense2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
AID215858Effective dose required to inhibit the growth of Trypanosoma brucei2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (120)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's19 (15.83)18.2507
2000's66 (55.00)29.6817
2010's32 (26.67)24.3611
2020's3 (2.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.65 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (0.85%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
Other117 (99.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]